Non-prescription Drugs Market Report

Europe Non-prescription Drugs Market Size, Status and Forecast 2014-2026

  • POSTDATE：Feb 06, 2020
  • PAGES：178
  • REPORT CODE：GMM462995
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Non-prescription Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 6.2% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Non-prescription Drugs Market Segmentations:

    By Player:

    • Merck & Co (MSD)

    • Takeda

    • Novo Nordisk

    • Johnson & Johnson

    • Boehringer Ingelheim

    • Bristol-Myers Squibb

    • Shire

    • Amgen

    • Merck & Co. (MSD)

    • Pfizer

    • Bayer

    • AbbVie

    • Allergan

    • Gilead Sciences

    • AstraZeneca

    • GlaxoSmithKline (GSK)

    • Roche

    • Sanofi

    • Eli Lilly

    • Teva

    By Type:

    • Brand Drugs

    • Generic Drug

    By End-User:

    • Hospital

    • Clinic

    • Other

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Non-prescription Drugs Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Non-prescription Drugs Market Size and Growth Rate of Brand Drugs from 2014 to 2026

    • 1.3.2 Europe Non-prescription Drugs Market Size and Growth Rate of Generic Drug from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Non-prescription Drugs Market Size and Growth Rate of Hospital from 2014 to 2026

    • 1.4.2 Europe Non-prescription Drugs Market Size and Growth Rate of Clinic from 2014 to 2026

    • 1.4.3 Europe Non-prescription Drugs Market Size and Growth Rate of Other from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Non-prescription Drugs Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Non-prescription Drugs by Major Types

      • 3.4.1 Market Size and Growth Rate of Brand Drugs

      • 3.4.2 Market Size and Growth Rate of Generic Drug

    4 Segmentation of Non-prescription Drugs Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Non-prescription Drugs by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Non-prescription Drugs for Hospital

      • 4.4.2 Market Size and Growth Rate of Non-prescription Drugs for Clinic

      • 4.4.3 Market Size and Growth Rate of Non-prescription Drugs for Other

    5 Market Analysis by Major Regions

    • 5.1 Europe Non-prescription Drugs Production Analysis by Top Regions

    • 5.2 Europe Non-prescription Drugs Consumption Analysis by Top Regions

    • 5.3 Europe Non-prescription Drugs Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Non-prescription Drugs Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Non-prescription Drugs Production, Import, Consumption and Export Analysis

      • 5.3.3 France Non-prescription Drugs Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Non-prescription Drugs Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Non-prescription Drugs Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Non-prescription Drugs Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Non-prescription Drugs Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Non-prescription Drugs Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Non-prescription Drugs Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-prescription Drugs Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Non-prescription Drugs Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Non-prescription Drugs Production, Import, Consumption and Export Analysis

    6 Product Circulation of Non-prescription Drugs Market among Top Countries

    • 6.1 Top 5 Export Countries in Non-prescription Drugs Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Non-prescription Drugs Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Non-prescription Drugs Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Non-prescription Drugs Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Non-prescription Drugs Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Non-prescription Drugs Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Non-prescription Drugs Landscape Analysis

    • 7.1 Germany Non-prescription Drugs Landscape Analysis by Major Types

    • 7.2 Germany Non-prescription Drugs Landscape Analysis by Major End-Users

    8. UK Non-prescription Drugs Landscape Analysis

    • 8.1 UK Non-prescription Drugs Landscape Analysis by Major Types

    • 8.2 UK Non-prescription Drugs Landscape Analysis by Major End-Users

    9. France Non-prescription Drugs Landscape Analysis

    • 9.1 France Non-prescription Drugs Landscape Analysis by Major Types

    • 9.2 France Non-prescription Drugs Landscape Analysis by Major End-Users

    10. Italy Non-prescription Drugs Landscape Analysis

    • 10.1 Italy Non-prescription Drugs Landscape Analysis by Major Types

    • 10.2 Italy Non-prescription Drugs Landscape Analysis by Major End-Users

    11. Spain Non-prescription Drugs Landscape Analysis

    • 11.1 Spain Non-prescription Drugs Landscape Analysis by Major Types

    • 11.2 Spain Non-prescription Drugs Landscape Analysis by Major End-Users

    12. Poland Non-prescription Drugs Landscape Analysis

    • 12.1 Poland Non-prescription Drugs Landscape Analysis by Major Types

    • 12.2 Poland Non-prescription Drugs Landscape Analysis by Major End-Users

    13. Russia Non-prescription Drugs Landscape Analysis

    • 13.1 Russia Non-prescription Drugs Landscape Analysis by Major Types

    • 13.2 Russia Non-prescription Drugs Landscape Analysis by Major End-Users

    14. Switzerland Non-prescription Drugs Landscape Analysis

    • 14.1 Switzerland Non-prescription Drugs Landscape Analysis by Major Types

    • 14.2 Switzerland Non-prescription Drugs Landscape Analysis by Major End-Users

    15. Turkey Non-prescription Drugs Landscape Analysis

    • 15.1 Turkey Non-prescription Drugs Landscape Analysis by Major Types

    • 15.2 Turkey Non-prescription Drugs Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-prescription Drugs Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-prescription Drugs Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-prescription Drugs Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-prescription Drugs Landscape Analysis by Top Countries

      • 16.3.1 Denmark Non-prescription Drugs Market Volume and Growth Rate

      • 16.3.2 Finland Non-prescription Drugs Market Volume and Growth Rate

      • 16.3.3 Norway Non-prescription Drugs Market Volume and Growth Rate

      • 16.3.4 Sweden Non-prescription Drugs Market Volume and Growth Rate

      • 16.3.6 Iceland Non-prescription Drugs Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Non-prescription Drugs Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Non-prescription Drugs Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Non-prescription Drugs Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Non-prescription Drugs Landscape Analysis by Top Countries

      • 17.3.1 Belgium Non-prescription Drugs Market Volume and Growth Rate

      • 17.3.2 Netherlands Non-prescription Drugs Market Volume and Growth Rate

      • 17.3.3 Luxembourg Non-prescription Drugs Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Non-prescription Drugs Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Non-prescription Drugs Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Non-prescription Drugs Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Non-prescription Drugs Landscape Analysis by Top Countries

      • 18.3.1 Estonia Non-prescription Drugs Market Volume and Growth Rate

      • 18.3.2 Latvia Non-prescription Drugs Market Volume and Growth Rate

      • 18.3.3 Lithuania Non-prescription Drugs Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Merck & Co (MSD)

      • 19.1.1 Merck & Co (MSD) Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Takeda

      • 19.2.1 Takeda Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Novo Nordisk

      • 19.3.1 Novo Nordisk Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Johnson & Johnson

      • 19.4.1 Johnson & Johnson Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Boehringer Ingelheim

      • 19.5.1 Boehringer Ingelheim Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Bristol-Myers Squibb

      • 19.6.1 Bristol-Myers Squibb Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Shire

      • 19.7.1 Shire Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Amgen

      • 19.8.1 Amgen Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Merck & Co. (MSD)

      • 19.9.1 Merck & Co. (MSD) Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Pfizer

      • 19.10.1 Pfizer Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 Bayer

      • 19.11.1 Bayer Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 AbbVie

      • 19.12.1 AbbVie Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 Allergan

      • 19.13.1 Allergan Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 Gilead Sciences

      • 19.14.1 Gilead Sciences Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 AstraZeneca

      • 19.15.1 AstraZeneca Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    • 19.16 GlaxoSmithKline (GSK)

      • 19.16.1 GlaxoSmithKline (GSK) Company Profile and Development Status

      • 19.16.2 Market Performance

      • 19.16.3 Product and Service Introduction

    • 19.17 Roche

      • 19.17.1 Roche Company Profile and Development Status

      • 19.17.2 Market Performance

      • 19.17.3 Product and Service Introduction

    • 19.18 Sanofi

      • 19.18.1 Sanofi Company Profile and Development Status

      • 19.18.2 Market Performance

      • 19.18.3 Product and Service Introduction

    • 19.19 Eli Lilly

      • 19.19.1 Eli Lilly Company Profile and Development Status

      • 19.19.2 Market Performance

      • 19.19.3 Product and Service Introduction

    • 19.20 Teva

      • 19.20.1 Teva Company Profile and Development Status

      • 19.20.2 Market Performance

      • 19.20.3 Product and Service Introduction

    The List of Tables and Figures (Totals 104 Figures and 130 Tables)

    • Figure Product Picture

    • Figure Europe Non-prescription Drugs Market Size and Growth Rate of Brand Drugs from 2014 to 2026

    • Figure Europe Non-prescription Drugs Market Size and Growth Rate of Generic Drug from 2014 to 2026

    • Figure Europe Non-prescription Drugs Market Size and Growth Rate of Hospital from 2014 to 2026

    • Figure Europe Non-prescription Drugs Market Size and Growth Rate of Clinic from 2014 to 2026

    • Figure Europe Non-prescription Drugs Market Size and Growth Rate of Other from 2014 to 2026

    • Figure Germany Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure UK Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure France Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Non-prescription Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Non-prescription Drugs Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Non-prescription Drugs

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Non-prescription Drugs by Different Types from 2014 to 2026

    • Table Consumption Share of Non-prescription Drugs by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Brand Drugs

    • Figure Market Size and Growth Rate of Generic Drug

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Non-prescription Drugs by Different End-Users from 2014 to 2026

    • Table Consumption Share of Non-prescription Drugs by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of Hospital

    • Figure Market Size and Growth Rate of Clinic

    • Figure Market Size and Growth Rate of Other

    • Table Europe Non-prescription Drugs Production by Major Regions

    • Table Europe Non-prescription Drugs Production Share by Major Regions

    • Figure Europe Non-prescription Drugs Production Share by Major Countries and Regions in 2014

    • Table Europe Non-prescription Drugs Consumption by Major Regions

    • Table Europe Non-prescription Drugs Consumption Share by Major Regions

    • Table Germany Non-prescription Drugs Production, Import, Consumption and Export Analysis

    • Table UK Non-prescription Drugs Production, Import, Consumption and Export Analysis

    • Table France Non-prescription Drugs Production, Import, Consumption and Export Analysis

    • Table Italy Non-prescription Drugs Production, Import, Consumption and Export Analysis

    • Table Spain Non-prescription Drugs Production, Import, Consumption and Export Analysis

    • Table Poland Non-prescription Drugs Production, Import, Consumption and Export Analysis

    • Table Russia Non-prescription Drugs Production, Import, Consumption and Export Analysis

    • Table Switzerland Non-prescription Drugs Production, Import, Consumption and Export Analysis

    • Table Turkey Non-prescription Drugs Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-prescription Drugs Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-prescription Drugs Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-prescription Drugs Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Non-prescription Drugs Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Non-prescription Drugs Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Non-prescription Drugs Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Non-prescription Drugs Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Non-prescription Drugs Consumption by Types from 2014 to 2026

    • Table Germany Non-prescription Drugs Consumption Share by Types from 2014 to 2026

    • Table Germany Non-prescription Drugs Consumption by End-Users from 2014 to 2026

    • Table Germany Non-prescription Drugs Consumption Share by End-Users from 2014 to 2026

    • Table UK Non-prescription Drugs Consumption by Types from 2014 to 2026

    • Table UK Non-prescription Drugs Consumption Share by Types from 2014 to 2026

    • Table UK Non-prescription Drugs Consumption by End-Users from 2014 to 2026

    • Table UK Non-prescription Drugs Consumption Share by End-Users from 2014 to 2026

    • Table France Non-prescription Drugs Consumption by Types from 2014 to 2026

    • Table France Non-prescription Drugs Consumption Share by Types from 2014 to 2026

    • Table France Non-prescription Drugs Consumption by End-Users from 2014 to 2026

    • Table France Non-prescription Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Italy Non-prescription Drugs Consumption by Types from 2014 to 2026

    • Table Italy Non-prescription Drugs Consumption Share by Types from 2014 to 2026

    • Table Italy Non-prescription Drugs Consumption by End-Users from 2014 to 2026

    • Table Italy Non-prescription Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Spain Non-prescription Drugs Consumption by Types from 2014 to 2026

    • Table Spain Non-prescription Drugs Consumption Share by Types from 2014 to 2026

    • Table Spain Non-prescription Drugs Consumption by End-Users from 2014 to 2026

    • Table Spain Non-prescription Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Poland Non-prescription Drugs Consumption by Types from 2014 to 2026

    • Table Poland Non-prescription Drugs Consumption Share by Types from 2014 to 2026

    • Table Poland Non-prescription Drugs Consumption by End-Users from 2014 to 2026

    • Table Poland Non-prescription Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Russia Non-prescription Drugs Consumption by Types from 2014 to 2026

    • Table Russia Non-prescription Drugs Consumption Share by Types from 2014 to 2026

    • Table Russia Non-prescription Drugs Consumption by End-Users from 2014 to 2026

    • Table Russia Non-prescription Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Non-prescription Drugs Consumption by Types from 2014 to 2026

    • Table Switzerland Non-prescription Drugs Consumption Share by Types from 2014 to 2026

    • Table Switzerland Non-prescription Drugs Consumption by End-Users from 2014 to 2026

    • Table Switzerland Non-prescription Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Non-prescription Drugs Consumption by Types from 2014 to 2026

    • Table Turkey Non-prescription Drugs Consumption Share by Types from 2014 to 2026

    • Table Turkey Non-prescription Drugs Consumption by End-Users from 2014 to 2026

    • Table Turkey Non-prescription Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-prescription Drugs Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-prescription Drugs Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-prescription Drugs Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-prescription Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-prescription Drugs Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-prescription Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Non-prescription Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Non-prescription Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Non-prescription Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Non-prescription Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Non-prescription Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-prescription Drugs Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-prescription Drugs Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-prescription Drugs Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-prescription Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-prescription Drugs Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-prescription Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Non-prescription Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Non-prescription Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Non-prescription Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-prescription Drugs Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-prescription Drugs Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-prescription Drugs Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-prescription Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-prescription Drugs Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-prescription Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Non-prescription Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Non-prescription Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Non-prescription Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Merck & Co (MSD)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Merck & Co (MSD)

    • Figure Sales and Growth Rate Analysis of Merck & Co (MSD)

    • Figure Revenue and Market Share Analysis of Merck & Co (MSD)

    • Table Product and Service Introduction of Merck & Co (MSD)

    • Table Company Profile and Development Status of Takeda

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Takeda

    • Figure Sales and Growth Rate Analysis of Takeda

    • Figure Revenue and Market Share Analysis of Takeda

    • Table Product and Service Introduction of Takeda

    • Table Company Profile and Development Status of Novo Nordisk

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novo Nordisk

    • Figure Sales and Growth Rate Analysis of Novo Nordisk

    • Figure Revenue and Market Share Analysis of Novo Nordisk

    • Table Product and Service Introduction of Novo Nordisk

    • Table Company Profile and Development Status of Johnson & Johnson

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Johnson & Johnson

    • Figure Sales and Growth Rate Analysis of Johnson & Johnson

    • Figure Revenue and Market Share Analysis of Johnson & Johnson

    • Table Product and Service Introduction of Johnson & Johnson

    • Table Company Profile and Development Status of Boehringer Ingelheim

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Boehringer Ingelheim

    • Figure Sales and Growth Rate Analysis of Boehringer Ingelheim

    • Figure Revenue and Market Share Analysis of Boehringer Ingelheim

    • Table Product and Service Introduction of Boehringer Ingelheim

    • Table Company Profile and Development Status of Bristol-Myers Squibb

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bristol-Myers Squibb

    • Figure Sales and Growth Rate Analysis of Bristol-Myers Squibb

    • Figure Revenue and Market Share Analysis of Bristol-Myers Squibb

    • Table Product and Service Introduction of Bristol-Myers Squibb

    • Table Company Profile and Development Status of Shire

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Shire

    • Figure Sales and Growth Rate Analysis of Shire

    • Figure Revenue and Market Share Analysis of Shire

    • Table Product and Service Introduction of Shire

    • Table Company Profile and Development Status of Amgen

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Amgen

    • Figure Sales and Growth Rate Analysis of Amgen

    • Figure Revenue and Market Share Analysis of Amgen

    • Table Product and Service Introduction of Amgen

    • Table Company Profile and Development Status of Merck & Co. (MSD)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Merck & Co. (MSD)

    • Figure Sales and Growth Rate Analysis of Merck & Co. (MSD)

    • Figure Revenue and Market Share Analysis of Merck & Co. (MSD)

    • Table Product and Service Introduction of Merck & Co. (MSD)

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer

    • Table Company Profile and Development Status of Bayer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bayer

    • Figure Sales and Growth Rate Analysis of Bayer

    • Figure Revenue and Market Share Analysis of Bayer

    • Table Product and Service Introduction of Bayer

    • Table Company Profile and Development Status of AbbVie

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AbbVie

    • Figure Sales and Growth Rate Analysis of AbbVie

    • Figure Revenue and Market Share Analysis of AbbVie

    • Table Product and Service Introduction of AbbVie

    • Table Company Profile and Development Status of Allergan

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Allergan

    • Figure Sales and Growth Rate Analysis of Allergan

    • Figure Revenue and Market Share Analysis of Allergan

    • Table Product and Service Introduction of Allergan

    • Table Company Profile and Development Status of Gilead Sciences

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Gilead Sciences

    • Figure Sales and Growth Rate Analysis of Gilead Sciences

    • Figure Revenue and Market Share Analysis of Gilead Sciences

    • Table Product and Service Introduction of Gilead Sciences

    • Table Company Profile and Development Status of AstraZeneca

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AstraZeneca

    • Figure Sales and Growth Rate Analysis of AstraZeneca

    • Figure Revenue and Market Share Analysis of AstraZeneca

    • Table Product and Service Introduction of AstraZeneca

    • Table Company Profile and Development Status of GlaxoSmithKline (GSK)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of GlaxoSmithKline (GSK)

    • Figure Sales and Growth Rate Analysis of GlaxoSmithKline (GSK)

    • Figure Revenue and Market Share Analysis of GlaxoSmithKline (GSK)

    • Table Product and Service Introduction of GlaxoSmithKline (GSK)

    • Table Company Profile and Development Status of Roche

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Roche

    • Figure Sales and Growth Rate Analysis of Roche

    • Figure Revenue and Market Share Analysis of Roche

    • Table Product and Service Introduction of Roche

    • Table Company Profile and Development Status of Sanofi

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi

    • Figure Sales and Growth Rate Analysis of Sanofi

    • Figure Revenue and Market Share Analysis of Sanofi

    • Table Product and Service Introduction of Sanofi

    • Table Company Profile and Development Status of Eli Lilly

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eli Lilly

    • Figure Sales and Growth Rate Analysis of Eli Lilly

    • Figure Revenue and Market Share Analysis of Eli Lilly

    • Table Product and Service Introduction of Eli Lilly

    • Table Company Profile and Development Status of Teva

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Teva

    • Figure Sales and Growth Rate Analysis of Teva

    • Figure Revenue and Market Share Analysis of Teva

    • Table Product and Service Introduction of Teva

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US